Chaparral Labs
back to publications

Publication

C-terminal truncation of GSK-3β enhances its dephosphorylation by PP2A.

Jin Nana, Wu Yue, Xu Wen, Gong Cheng-Xin, Iqbal Khalid, Liu Fei

disease:ad

Abstract

Glycogen synthase kinase-3β (GSK-3β) is the major tau kinase. Its phosphorylation at Ser9 suppresses the activity. In Alzheimer's disease (AD) brain, GSK-3β is truncated at the C terminus by overactivated calpain I, leading to an increase in its activity. However, the effect of truncation on its phosphorylation is unknown. We found here that in AD brain and in cultured cells, C-terminally truncated GSK-3β is less phosphorylated at Ser9 than the full-length enzyme. The truncation promotes GSK-3β nuclear translocation and enhances its interaction with protein phosphatase 2A (PP2A), leading to dephosphorylation. Thus, the truncation of GSK-3β may enhance its activity through Ser9 dephosphorylation by PP2A. Our findings shed new light on the role of calpain-GSK-3β-PP2A in tau pathogenesis of AD.

MeSH Terms

Active Transport, Cell NucleusAged, 80 and overAlzheimer DiseaseAnimalsAutopsyBlotting, WesternBrainCell Line, TumorFemaleGlycogen Synthase Kinase 3 betaHEK293 CellsHeLa CellsHumansMaleMicroscopy, ConfocalMutationPhosphorylationPostmortem ChangesProtein BindingProtein Phosphatase 2SerineTime Factors